Fully revised and updated, the third edition of this full-color chart collects many of the most clinically useful tables, algorithms, and other items from the Red Book, 33rd Edition and presents them in an enlarged, enhanced colorized format that is lightweight, portable, and easy to navigate.
Additionally, new tables have been created exclusively for this chart, synthesizing important clinical information from the Red Book text.
Topics include:
- Staphylococcal Infections
- Streptococcal Infections
- COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)
- Diarrheal Infections
- Immunizations
- Antibiotic Prophylaxis
- Immune Globulin
- Kawasaki Disease
- Tuberculosis
- Lyme Disease
- Varicella-Zoster
- Fungal Infections
- Genital and Neonatal Herpes
- Syphilis
- HIV
- Immunocompromised Children and Adolescents
Fully revised and updated, the third edition of this full-color chart collects many of the most clinically useful tables, algorithms, and other items from the
Red Book, 33rd Edition and presents them in an enlarged, enhanced colorized format that is lightweight, portable, and easy to navigate.
1. Systems-Based Treatment
2. Syphilis
3. Herpes Infections
4. HIV Infections
5. Hepatitis C / Cytomegalovirus
6. Kawasaki Disease
7. Multisystem Inflammatory Syndrome in Children (MIS-C)
8. Streptococcal and Staphylococcal Infections
9. Lyme Disease
10. Immunizations
11. Infection Control in Child Care
12. Tuberculosis
13. Varicella-Zoster
14. Head Lice / Tetanus
15. Immune Globulin
16. Antibiotic Prophylaxis
David W. Kimberlin, MD, FAAP, is the Editor of the 2021 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 and 2018 editions, and was an Associate Editor of the 2012 and 2009 editions, and served on the AAP Committee on Infectious Diseases from 2005- 2011. Dr Kimberlin is Professor of Pediatrics and Co-director, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham. His clinical and research interests include pediatric infectious diseases, antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome.
